Status:
COMPLETED
Dental Safety Profile of High-Dose Radioiodine Therapy
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Thyroid Cancer
Eligibility:
All Genders
Brief Summary
We aim to assess the incidence of oral and dental adverse events after high-dose radioiodine therapy for differentiated thyroid cancer.
Detailed Description
Sialadenitis and xerostomia are the most frequent adverse events of high-dose radioiodine therapy. Saliva has vital functions in maintaining periodontal and oral health. Therefore, xerostomia not only...
Eligibility Criteria
Inclusion
- histologically confirmed differentiated thyroid cancer
- status after total thyroidectomy
- status after subsequent high-dose radioiodine treatment
- regular follow-up by a board-certified dentist
- a minimum follow-up of 1 year after radioiodine therapy.
Exclusion
- anaplastic thyroid cancer
Key Trial Info
Start Date :
September 1 2004
Trial Type :
OBSERVATIONAL
End Date :
September 1 2006
Estimated Enrollment :
202 Patients enrolled
Trial Details
Trial ID
NCT00439478
Start Date
September 1 2004
End Date
September 1 2006
Last Update
November 14 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Basel, Switzerland, 4031